Copyright © 2011 Akiko Okamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. S. Sakaguchi, “Naturally arising CD4⁺ regulatory T cells for immunologic self-tolerance and negative control of immune responses,” Annual Review of Immunology, vol. 22, pp. 531–562, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
2. S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” Cell, vol. 133, no. 5, pp. 775–787, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. A. Sharabi and E. Mozes, “Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases,” Immunotherapy, vol. 1, no. 3, pp. 385–401, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. J. C. Crispin, A. Martínez, and J. Alcocer-Varela, “Quantification of regulatory T cells in patients with systemic lupus erythematosus,” Journal of Autoimmunity, vol. 21, no. 3, pp. 273–276, 2003. View at Publisher · View at Google Scholar · View at Scopus
5. X. Valencia, C. Yarboro, G. Illei, and P. E. Lipsky, “Deficient CD4⁺CD25^high T regulatory cell function in patients with active systemic lupus erythematosus,” Journal of Immunology, vol. 178, no. 4, pp. 2579–2588, 2007. View at Scopus
6. B. H. Hahn, M. Anderson, E. Le, and A. la Cava, “Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2488–2497, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. M. Miyara, Z. Amoura, C. Parizot et al., “Global natural regulatory T cell depletion in active systemic lupus erythematosus,” Journal of Immunology, vol. 175, no. 12, pp. 8392–8400, 2005. View at Scopus
8. M. Miyara, Y. Yoshioka, A. Kitoh et al., “Functional delineation and differentiation dynamics of human CD4⁺ T cells expressing the FoxP3 transcription factor,” Immunity, vol. 30, no. 6, pp. 899–911, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. H. Y. Wu and N. A. Staines, “A deficiency of CD4⁺CD25⁺ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen,” Lupus, vol. 13, no. 3, pp. 192–200, 2004. View at Scopus
10. Y. Chen, C. Cuda, and L. Morel, “Genetic determination of T cell help in loss of tolerance to nuclear antigens,” Journal of Immunology, vol. 174, no. 12, pp. 7692–7702, 2005. View at Scopus
11. V. Parietti, F. Monneaux, M. Décossas, and S. Muller, “Function of CD4⁺,CD25⁺ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells,” Arthritis and Rheumatism, vol. 58, no. 6, pp. 1751–1761, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. J. Abe, S. Ueha, J. Suzuki, Y. Tokano, K. Matsushima, and S. Ishikawa, “Increased Foxp3⁺ CD4⁺ regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus,” American Journal of Pathology, vol. 173, no. 6, pp. 1682–1692, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. K. J. Scalapino, Q. Tang, J. A. Bluestone, M. L. Bonyhadi, and D. I. Daikh, “Suppression of disease in New Zealand black/New Zealand white lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells,” Journal of Immunology, vol. 177, no. 3, pp. 1451–1459, 2006. View at Scopus
14. H. K. Kang, M. A. Michaels, B. R. Berner, and S. K. Datta, “Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets,” Journal of Immunology, vol. 174, no. 6, pp. 3247–3255, 2005. View at Scopus
15. A. Sharabi, H. Zinger, M. Zborowsky, Z. M. Sthoeger, and E. Mozes, “A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4⁺CD25⁺ cells and TGF-β,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 23, pp. 8810–8815, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. A. la Cava, F. M. Ebling, and B. H. Hahn, “Ig-reactive CD4⁺CD25⁺ T cells from tolerized (New Zealand black × New Zealand white)F1 mice suppress in vitro production of antibodies to DNA,” Journal of Immunology, vol. 173, no. 5, pp. 3542–3548, 2004. View at Scopus
17. Y. Ozaki, R. Amakawa, T. Ito et al., “Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus,” Arthritis and Rheumatism, vol. 44, no. 2, pp. 432–441, 2001. View at Publisher · View at Google Scholar
18. K. V. Tarbell, L. Petit, X. Zuo et al., “Dendritic cell-expanded, islet-specific CD4⁺ CD25⁺ CD62L⁺ regulatory T cells restore normoglycemia in diabetic NOD mice,” Journal of Experimental Medicine, vol. 204, no. 1, pp. 191–201, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
19. E. L. Masteller, M. R. Warner, Q. Tang, K. V. Tarbell, H. McDevitt, and J. A. Bluestone, “Expansion of functional endogenous antigen-specific CD4⁺CD25⁺ regulatory T cells from nonobese diabetic mice,” Journal of Immunology, vol. 175, no. 5, pp. 3053–3059, 2005. View at Scopus
20. S. Mendlovic, S. Brocke, Y. Shoenfeld et al., “Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 7, pp. 2260–2264, 1988. View at Publisher · View at Google Scholar · View at Scopus
21. J. M. Phillips, N. M. Parish, M. Drage, and A. Cooke, “Cutting edge: interactions through the IL-10 receptor regulate autoimmune diabetes,” Journal of Immunology, vol. 167, no. 11, pp. 6087–6091, 2001. View at Scopus
22. A. Gonzalez, I. Andre-Schmutz, C. Carnaud, D. Mathis, and C. Benoist, “Damage control, rather than unresponsiveness, effected by protective DX5⁺T cells in autoimmune diabetes,” Nature Immunology, vol. 2, no. 12, pp. 1117–1125, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
23. F. J. Barrat, D. J. Cua, A. Boonstra et al., “In vitro generation of interleukin 10-producing regulatory CD4⁺ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines,” Journal of Experimental Medicine, vol. 195, no. 5, pp. 603–616, 2002. View at Publisher · View at Google Scholar · View at Scopus
24. E. M. Shevach, “CD4⁺CD25⁺ suppressor T cells: more questions than answers,” Nature Reviews Immunology, vol. 2, no. 6, pp. 389–400, 2002. View at Scopus
25. J. Rönnelid, A. Tejde, L. Mathsson, K. Nilsson-Ekdahl, and B. Nilsson, “Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcγRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE,” Annals of the Rheumatic Diseases, vol. 62, no. 1, pp. 37–42, 2003. View at Publisher · View at Google Scholar · View at Scopus
26. K. H. Sun, C. L. Yu, S. J. Tang, and G. H. Sun, “Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1β, IL-6, IL-8, IL-10 and TNF-α from normal human mononuclear cells involving in the lupus pathogenesis,” Immunology, vol. 99, no. 3, pp. 352–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
27. K. W. Moore, R. de Waal-Malefyt, R. L. Coffman, and A. O'Garra, “Interleukin-10 and the interleukin-10 receptor,” Annual Review of Immunology, vol. 19, pp. 683–765, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. G. Cai, R. A. Kastelein, and C. A. Hunter, “IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-γ when combined with IL-18,” European Journal of Immunology, vol. 29, no. 9, pp. 2658–2665, 1999. View at Scopus
29. W. S. Uhm, K. Na, G. W. Song et al., “Cytokine balance in kidney tissue from lupus nephritis patients,” Rheumatology, vol. 42, no. 8, pp. 935–938, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
30. F. Mackay, S. A. Woodcock, P. Lawton et al., “Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations,” Journal of Experimental Medicine, vol. 190, no. 11, pp. 1697–1710, 1999. View at Publisher · View at Google Scholar · View at Scopus
31. J. A. Gross, J. Johnston, S. Mudri et al., “TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease,” Nature, vol. 404, no. 6781, pp. 995–999, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. B. D. Hondowicz, S. T. Alexander, W. J. Quinn 3rd et al., “The role of BLyS/BLyS receptors in anti-chromatin B cell regulation,” International Immunology, vol. 19, no. 4, pp. 465–475, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. J. S. Thompson, P. Schneider, S. L. Kalled et al., “BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population,” Journal of Experimental Medicine, vol. 192, no. 1, pp. 129–135, 2000. View at Publisher · View at Google Scholar · View at Scopus
34. F. A. Houssiau, C. Lefebvre, M. V. Berghe, M. Lambert, J. P. Devogelaer, and J. C. Renauld, “Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity,” Lupus, vol. 4, no. 5, pp. 393–395, 1995. View at Scopus
35. H. Ishida, T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard, “Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice,” Journal of Experimental Medicine, vol. 179, no. 1, pp. 305–310, 1994. View at Publisher · View at Google Scholar · View at Scopus
36. C. T. Ravirajan, Y. Wang, L. A. Matis et al., “Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody,” Rheumatology, vol. 43, no. 4, pp. 442–447, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. B. R. Lauwerys, N. Garot, J. C. Renauld, and F. A. Houssiau, “Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients,” Arthritis and Rheumatism, vol. 43, no. 9, pp. 1976–1981, 2000. View at Publisher · View at Google Scholar · View at Scopus
38. L. Llorente, Y. Richaud-Patin, C. Garcia-Padilla et al., “Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic Lupus erythematosus,” Arthritis and Rheumatism, vol. 43, no. 8, pp. 1790–1800, 2000. View at Publisher · View at Google Scholar
39. V. Moulin, F. Andris, K. Thielemans, C. Maliszewski, J. Urbain, and M. Moser, “B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation,” Journal of Experimental Medicine, vol. 192, no. 4, pp. 475–482, 2000. View at Publisher · View at Google Scholar · View at Scopus
40. A. M. Jacobi, M. Odendahl, K. Reiter et al., “Correlation between circulating CD27^high plasma cells and disease activity in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 48, no. 5, pp. 1332–1342, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. G. Gröndal, H. Kristjansdottir, B. Gunnlaugsdottir et al., “Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in icelandic multicase families,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1649–1654, 1999. View at Publisher · View at Google Scholar · View at Scopus
42. M. W. van der Linden, R. G. Westendorp, A. Sturk, W. Bergman, and T. W. J. Huizinga, “High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus,” Journal of Investigative Medicine, vol. 48, no. 5, pp. 327–334, 2000. View at Scopus
43. M. E. Alarcon-Riquelme, A. K. B. Lindqvist, I. Jonasson et al., “Genetic analysis of the contribution of IL10 to systemic lupus erythematosus,” Journal of Rheumatology, vol. 26, no. 10, pp. 2148–2152, 1999.
44. X. Zhang, L. Giangreco, H. E. Broome, C. M. Dargan, and S. L. Swain, “Control of CD4 effector fate: transforming growth factor β1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion,” Journal of Experimental Medicine, vol. 182, no. 3, pp. 699–709, 1995. View at Publisher · View at Google Scholar · View at Scopus
45. T. Okamura, K. Fujio, M. Shibuya et al., “CD4⁺CD25-LAG3⁺ regulatory T cells controlled by the transcription factor Egr-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 13974–13979, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. S. Huber, N. Gagliani, E. Esplugues et al., “Th17 cells express interleukin-10 receptor and are controlled by Foxp3^- and Foxp3⁺ regulatory CD4⁺ T cells in an interleukin-10-dependent manner,” Immunity, vol. 34, no. 4, pp. 554–565, 2011. View at Publisher · View at Google Scholar · View at PubMed
47. H. C. Hsu, P. A. Yang, J. Wang et al., “Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice,” Nature Immunology, vol. 9, no. 2, pp. 166–175, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. C. K. Wong, L. C. Lit, L. S. Tam, E. K. Li, P. T. Wong, and C. W. Lam, “Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity,” Clinical Immunology, vol. 127, no. 3, pp. 385–393, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. J. C. Crispin, M. Oukka, G. Bayliss et al., “Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys,” Journal of Immunology, vol. 181, no. 12, pp. 8761–8766, 2008. View at Scopus
50. Y. Wang, S. Ito, Y. Chino et al., “Use of laser microdissection in the analysis of renal-infiltrating T cells in MRL/lpr mice,” Modern Rheumatology, vol. 18, no. 4, pp. 385–393, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. K. J. Maloy and F. Powrie, “Regulatory T cells in the control of immune pathology,” Nature Immunology, vol. 2, no. 9, pp. 816–822, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. L. Gorelik and R. A. Flavell, “Transforming growth factor-β in T-cell biology,” Nature Reviews Immunology, vol. 2, no. 1, pp. 46–53, 2002. View at Scopus
53. L. Gorelik, S. Constant, and R. A. Flavell, “Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation,” Journal of Experimental Medicine, vol. 195, no. 11, pp. 1499–1505, 2002. View at Publisher · View at Google Scholar · View at Scopus
54. V. L. Heath, E. E. Murphy, C. Crain, M. G. Tomlinson, and A. O'Garra, “TGF-β1 down-regulates Th2 development and results in decreased IL-4-induced STAT6 activation and GATA-3 expression,” European Journal of Immunology, vol. 30, no. 9, pp. 2639–2649, 2000. View at Publisher · View at Google Scholar · View at Scopus
55. C. A. Piccirillo, J. J. Letterio, A. M. Thornton et al., “CD4⁺CD25⁺ regulatory T cells can mediate suppressor function in the absence of transforming growth factor β1 production and responsiveness,” Journal of Experimental Medicine, vol. 196, no. 2, pp. 237–246, 2002. View at Publisher · View at Google Scholar · View at Scopus
56. S. Yamagiwa, J. D. Gray, S. Hashimoto, and D. A. Horwitz, “A role for TGF-β in the generation and expansion of CD4⁺CD25⁺ regulatory T cells from human peripheral blood,” Journal of Immunology, vol. 166, no. 12, pp. 7282–7289, 2001. View at Scopus
57. K. Kretschmer, I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer, “Inducing and expanding regulatory T cell populations by foreign antigen,” Nature Immunology, vol. 6, no. 12, pp. 1219–1227, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
58. S. Huber, C. Schramm, H. A. Lehr et al., “Cutting edge: TGF-β signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4⁺CD25⁺ T cells,” Journal of Immunology, vol. 173, no. 11, pp. 6526–6531, 2004. View at Scopus
59. Y. Tone, K. Furuuchi, Y. Kojima, M. L. Tykocinski, M. I. Greene, and M. Tone, “Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer,” Nature Immunology, vol. 9, no. 2, pp. 194–202, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
60. A. Samanta, B. Li, X. Song et al., “TGF-β and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 37, pp. 14023–14027, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
61. T. Oida, L. Xu, H. L. Weiner, A. Kitani, and W. Strober, “TGF-β-mediated suppression by CD4⁺CD25⁺ T cells is facilitated by CTLA-4 signaling,” Journal of Immunology, vol. 177, no. 4, pp. 2331–2339, 2006. View at Scopus
62. L. Fahlén, S. Read, L. Gorelik et al., “T cells that cannot respond to TGF-β escape control by CD4⁺ CD25⁺ regulatory T cells,” Journal of Experimental Medicine, vol. 201, no. 5, pp. 737–746, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
63. H. von Boehmer, “Mechanisms of suppression by suppressor T cells,” Nature Immunology, vol. 6, no. 4, pp. 338–344, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. Q. Xing, H. Su, J. Cui, and B. Wang, “Role of Treg cells and TGF-β1 in patients with systemic lupus erythematosus: a possible relation with lupus nephritis,” Immunological Investigations, 2011. View at Publisher · View at Google Scholar · View at PubMed
65. A. M. Hammad, H. M. Youssef, and M. M. El-Arman, “Transforming growth factor β 1 in children with systemic lupus erythematosus: a possible relation with clinical presentation of lupus nephritis,” Lupus, vol. 15, no. 9, pp. 608–612, 2006. View at Publisher · View at Google Scholar · View at Scopus
66. V. Saxena, D. W. Lienesch, M. Zhou et al., “Dual roles of immunoregulatory cytokine TGF-β in the pathogenesis of autoimmunity-mediated organ damage,” Journal of Immunology, vol. 180, no. 3, pp. 1903–1912, 2008. View at Scopus
67. S. Pflanz, J. C. Timans, J. Cheung et al., “IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4⁺ T cells,” Immunity, vol. 16, no. 6, pp. 779–790, 2002. View at Publisher · View at Google Scholar
68. H. F. Pan, J. H. Tao, and D. Q. Ye, “Therapeutic potential of IL-27 in systemic lupus erythematosus,” Expert Opinion on Therapeutic Targets, vol. 14, no. 5, pp. 479–484, 2010. View at Publisher · View at Google Scholar · View at PubMed
69. H. H. Smits, A. J. van Beelen, C. Hessle et al., “Commensal gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development,” European Journal of Immunology, vol. 34, no. 5, pp. 1371–1380, 2004. View at Publisher · View at Google Scholar · View at PubMed
70. Y. Sonobe, I. Yawata, J. Kawanokuchi, H. Takeuchi, T. Mizuno, and A. Suzumura, “Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations,” Brain Research, vol. 1040, no. 1-2, pp. 202–207, 2005. View at Publisher · View at Google Scholar · View at PubMed
71. J. S. Stumhofer, A. Laurence, E. H. Wilson et al., “Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system,” Nature Immunology, vol. 7, no. 9, pp. 937–945, 2006. View at Publisher · View at Google Scholar · View at PubMed
72. J. S. Stumhofer and C. A. Hunter, “Advances in understanding the anti-inflammatory properties of IL-27,” Immunology Letters, vol. 117, no. 2, pp. 123–130, 2008. View at Publisher · View at Google Scholar · View at PubMed
73. J. Liu, X. Guan, and X. Ma, “Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-γ-mediated pathways,” Journal of Experimental Medicine, vol. 204, no. 1, pp. 141–152, 2007. View at Publisher · View at Google Scholar · View at PubMed
74. S. Wirtz, C. Becker, M. C. Fantini et al., “EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-κB activation,” Journal of Immunology, vol. 174, no. 5, pp. 2814–2824, 2005.
75. T. Yoshimura, A. Takeda, S. Hamano et al., “Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4⁺ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4⁺ T cells partially through STAT3-dependent mechanism,” Journal of Immunology, vol. 177, no. 8, pp. 5377–5385, 2006.
76. L. Hibbert, S. Pflanz, R. de Waal-Malefyt, and R. A. Kastelein, “IL-27 and IFN-α signal via STAT1 and STAT3 and induce T-Bet and IL-12Rβ2 in naive T cells,” Journal of Interferon and Cytokine Research, vol. 23, no. 9, pp. 513–522, 2003. View at Publisher · View at Google Scholar · View at PubMed
77. A. Takeda, S. Hamano, A. Yamanaka et al., “Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment,” Journal of Immunology, vol. 170, no. 10, pp. 4886–4890, 2003.
78. D. Artis, A. Villarino, M. Silverman et al., “The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity,” Journal of Immunology, vol. 173, no. 9, pp. 5626–5634, 2004.
79. N. Ouaked, P. Y. Mantel, C. Bassin et al., “Regulation of the foxp3 gene by the Th1 cytokines: the role of IL-27-induced STAT1,” Journal of Immunology, vol. 182, no. 2, pp. 1041–1049, 2009.
80. H. Yoshida, M. Nakaya, and Y. Miyazaki, “Interleukin 27: a double-edged sword for offense and defense,” Journal of Leukocyte Biology, vol. 86, no. 6, pp. 1295–1303, 2009. View at Publisher · View at Google Scholar · View at PubMed
81. H. Yoshida, S. Hamano, G. Senaldi et al., “WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection,” Immunity, vol. 15, no. 4, pp. 569–578, 2001. View at Publisher · View at Google Scholar
82. Q. Chen, N. Ghilardi, H. Wang et al., “Development of Th1-type immune responses requires the type I cytokine receptor TCCR,” Nature, vol. 407, no. 6806, pp. 916–920, 2000. View at Publisher · View at Google Scholar · View at PubMed
83. S. Lucas, N. Ghilardi, J. Li, and F. J. de Sauvage, “IL-27 regulates IL-12 responsiveness of naïve CD4⁺ T cells through STAT1-dependent and -independent mechanisms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15047–15052, 2003. View at Publisher · View at Google Scholar · View at PubMed
84. S. Wang, Y. Miyazaki, Y. Shinozaki, and H. Yoshida, “Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1(IL-27R) deficiency,” Journal of Immunology, vol. 179, no. 10, pp. 6421–6428, 2007.
85. J. S. Stumhofer, J. S. Silver, A. Laurence et al., “Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10,” Nature Immunology, vol. 8, no. 12, pp. 1363–1371, 2007. View at Publisher · View at Google Scholar · View at PubMed
86. A. Awasthi, Y. Carrier, J. P. Peron et al., “A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells,” Nature Immunology, vol. 8, no. 12, pp. 1380–1389, 2007. View at Publisher · View at Google Scholar · View at PubMed
87. G. Murugaiyan, A. Mittal, R. Lopez-Diego, L. M. Maier, D. E. Anderson, and H. L. Weiner, “IL-27 is a key regulator of IL-10 and IL-17 production by human CD4⁺ T cells,” Journal of Immunology, vol. 183, no. 4, pp. 2435–2443, 2009. View at Publisher · View at Google Scholar · View at PubMed
88. C. Diveu, M. J. McGeachy, K. Boniface et al., “IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells,” Journal of Immunology, vol. 182, no. 9, pp. 5748–5756, 2009. View at Publisher · View at Google Scholar · View at PubMed
89. D. C. Fitzgerald, G. X. Zhang, M. El-Behi et al., “Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells,” Nature Immunology, vol. 8, no. 12, pp. 1372–1379, 2007. View at Publisher · View at Google Scholar · View at PubMed
90. M. Batten, N. M. Kljavin, J. Li, M. J. Walter, F. J. de Sauvage, and N. Ghilardi, “Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells,” Journal of Immunology, vol. 180, no. 5, pp. 2752–2756, 2008.
91. M. G. Roncarolo, S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings, “Interleukin-10-secreting type 1 regulatory T cells in rodents and humans,” Immunological Reviews, vol. 212, pp. 28–50, 2006. View at Publisher · View at Google Scholar · View at PubMed
92. C. Pot, H. Jin, A. Awasthi et al., “Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells,” Journal of Immunology, vol. 183, no. 2, pp. 797–801, 2009. View at Publisher · View at Google Scholar · View at PubMed
93. S. Shimizu, N. Sugiyama, K. Masutani et al., “Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1),” Journal of Immunology, vol. 175, no. 11, pp. 7185–7192, 2005.
94. T. Igawa, H. Nakashima, A. Sadanaga et al., “Deficiency in EBV-induced gene 3 (EBI3) in MRL/lpr mice results in pathological alteration of autoimmune glomerulonephritis and sialadenitis,” Modern Rheumatology, vol. 19, no. 1, pp. 33–41, 2009. View at Publisher · View at Google Scholar · View at PubMed
95. N. Sugiyama, H. Nakashima, T. Yoshimura et al., “Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor α(WSX-1),” Annals of the Rheumatic Diseases, vol. 67, no. 10, pp. 1461–1467, 2008. View at Publisher · View at Google Scholar · View at PubMed
96. K. Teramoto, N. Negoro, K. Kitamoto et al., “Microarray analysis of glomerular gene expression in murine lupus nephritis,” Journal of Pharmacological Sciences, vol. 106, no. 1, pp. 56–67, 2008. View at Publisher · View at Google Scholar
97. T. T. Li, T. Zhang, G. M. Chen et al., “Low level of serum interleukin 27 in patients with systemic lupus erythematosus,” Journal of Investigative Medicine, vol. 58, no. 5, pp. 737–739, 2010. View at Publisher · View at Google Scholar · View at PubMed
98. M. Batten, N. Ramamoorthi, N. M. Kljavin et al., “IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells,” Journal of Experimental Medicine, vol. 207, no. 13, pp. 2895–2906, 2010. View at Publisher · View at Google Scholar · View at PubMed
99. L. W. Collison and D. A. A. Vignali, “Interleukin-35: odd one out or part of the family?” Immunological Reviews, vol. 226, no. 1, pp. 248–262, 2008. View at Publisher · View at Google Scholar · View at PubMed
100. M. Bettini and D. A. Vignali, “Regulatory T cells and inhibitory cytokines in autoimmunity,” Current Opinion in Immunology, vol. 21, no. 6, pp. 612–618, 2009. View at Publisher · View at Google Scholar · View at PubMed
101. L. W. Collison, C. J. Workman, T. T. Kuo et al., “The inhibitory cytokine IL-35 contributes to regulatory T-cell function,” Nature, vol. 450, no. 7169, pp. 566–569, 2007. View at Publisher · View at Google Scholar · View at PubMed
102. W. Niedbala, X. Q. Wei, B. Cai et al., “IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells,” European Journal of Immunology, vol. 37, no. 11, pp. 3021–3029, 2007. View at Publisher · View at Google Scholar · View at PubMed
103. D. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” Nature Reviews Immunology, vol. 8, no. 7, pp. 523–532, 2008. View at Publisher · View at Google Scholar · View at PubMed
104. Q. Tang and J. A. Bluestone, “The Foxp3⁺ regulatory T cell: a jack of all trades, master of regulation,” Nature Immunology, vol. 9, no. 3, pp. 239–244, 2008. View at Publisher · View at Google Scholar · View at PubMed